Skip to main content

Supportive care and survivorship

News and opinion

15-11-2018 | Prostate cancer | Podcast | Audio

Researcher comment: COMPARE study

Hashim Ahmed takes us through the COMPARE study – presented at NCRI 2018 – which showed that men with localized prostate cancer are willing to make accept lower survival odds for a better quality of life. He outlines the key findings, the implications of the results for physicians, and the next steps for research (5:36).

Click here for the accompanying news story.

09-11-2018 | Prostate cancer | News

NCRI 2018 in brief

Prostate cancer patients willing to make trade-offs between survival, side effects

Men with a new diagnosis of nonmetastatic prostate cancer say they would accept small reductions in survival odds if that meant fewer side effects and an improved quality of life, suggests the COMPARE study.

10-10-2018 | Chemotherapy | News

Short-term hospitalization, mortality risk varies by palliative chemotherapy regimen

Two independent studies of older patients receiving initial chemotherapy for metastatic breast cancer or non-small-cell lung cancer have found that the risk for hospitalization or death may be predicted by the cytotoxic regimen used.


Cancer 2018; doi:10.1002/cncr.31760
JAMA Network Open 2018; 1: e183023

09-10-2018 | EMA | News


Brigatinib, paclitaxel, biosimilar pegfilgrastims receive EMA approvals

Read more on these decisions here

08-10-2018 | Quality of life | News

Improved PFS does not equate to improved HRQoL in patients with cancer

Progression-free survival should not be used as a surrogate marker for health-related quality of life as there is no correlation between them, results of a systematic review and quantitative analysis of randomized clinical trials show.


JAMA Intern Med 2018; doi:10.1001/jamainternmed.2018.4710

02-10-2018 | Non-small cell lung cancer | News

News in brief

Surgery type may predict long-term opioid use in early-stage NSCLC

Patients who undergo video-assisted thoracoscopic surgery for stage I non-small-cell lung cancer are less likely to become long-term opioid users than their counterparts undergoing the conventional open procedure, findings suggest.

18-09-2018 | Supportive care | News

Allogeneic HSCT-treated patients often receive medically intense end-of-life care

A US research team has found that end-of-life care among individuals who undergo allogeneic hematopoietic stem cell transplantation can often be medically intense.


J Clin Oncol 2018; doi:10.1200/JCO.2018.78.095

13-09-2018 | Castration-resistant prostate cancer | News

News in brief

SPARTAN: Adding apalutamide to ADT does not diminish nonmetastatic CRPC HRQoL

Men with high-risk nonmetastatic castration-resistant prostate cancer do not report a deterioration in health-related quality of life when androgen deprivation therapy is supplemented with apalutamide, indicate SPARTAN trial results.

03-09-2018 | Advanced breast cancer | News

EMBRACA results demonstrate talazoparib advanced breast cancer benefits

The PARP inhibitor talazoparib extends progression-free survival and improves quality of life compared with standard chemotherapy, show findings from the phase III EMBRACA study of women with advanced breast cancer and a germline BRCA1/2 mutation.


N Engl J Med 2018; 379: 753–763
Ann Oncol 2018; doi:10.1093/annonc/mdy257

03-08-2018 | Hodgkin lymphoma | News

News in brief

‘Reassuring’ childbirth rate reported for Hodgkin lymphoma survivors

The birth rate for women who are relapse-free after treatment for Hodgkin lymphoma has risen in recent years, becoming comparable with that of the general population regardless of disease stage or treatment.

30-07-2018 | FDA | News


Ivosidenib, filgrastim biosimilar receive approvals

Click here to read more on these US FDA decisions

10-07-2018 | Breast cancer | News

Acupuncture benefits unclear for aromatase inhibitor–related athralgia

Acupuncture may provide modest reductions in aromatase inhibitor-related joint pain in postmenopausal women with early-stage breast cancer, results of a multicenter study suggest.


JAMA 2018; 320: 167–176

01-06-2018 | Survivorship | ASCO 2018 | News

Cognitive behavioral therapy more effective than acupuncture for insomnia in cancer survivors

Trial results suggest that cognitive behavioral therapy for insomnia is more effective than acupuncture for reducing the severity of insomnia symptoms in cancer survivors, although both approaches offer benefits.


ASCO Annual Meeting 2018; Chicago, Illinois, USA

21-05-2018 | FDA | News | Article


Epoetin alfa biosimilar approved for chemotherapy-related anemia

Click through for more on this US FDA announcement

16-05-2018 | Non-small cell lung cancer | News

News in brief

Advanced NSCLC patient outcomes also support osimertinib over chemotherapy

Patient-reported outcomes and quality of life are better with second-line osimertinib than chemotherapy in patients with T790M-positive advanced non-small-cell lung cancer, shows an analysis of the AURA 3 trial.

25-04-2018 | Breast cancer | News

GEC-ESTRO: Long-term QoL outcomes similar regardless of irradiation choice

Women with early breast cancer have similar quality of life at 5 years whether they are treated with accelerated partial breast irradiation using multicatheter brachytherapy or whole-breast irradiation, GEC-ESTRO data show.


ESTRO 2018; Spain, Barcelona, Lancet Oncol 2018; Advance online publication

23-04-2018 | Survivorship | Editorial | Article

Challenges of an aging and increasingly obese breast cancer survivor population: Are we ready?

In an aging population with rising obesity levels, comorbidities and worse overall prognoses for breast cancer patients are a growing concern. Damien Hansra (Cancer Treatment Centers of America, GA, USA) calls for more education and preparation to combat this concerning public health threat.

Damien Hansra MD

06-04-2018 | Urothelial cancer | News

News in brief

Positive HRQoL results for pembrolizumab in advanced urothelial cancer

Health-related quality of life analyses from the KEYNOTE-045 phase III study show that pembrolizumab prolongs time to deterioration in previously treated patients with advanced urothelial cancer compared with chemotherapy.

22-03-2018 | Prostate cancer | News

News in brief

CHAARTED metastatic prostate cancer QoL findings favor docetaxel

In men with metastatic hormone-sensitive prostate cancer, the addition of docetaxel to androgen deprivation therapy leads to an initial dip in quality of life, with a subsequent benefit over time, show CHAARTED results published in the Journal of Clinical Oncology.

02-03-2018 | Breast cancer | News

In other news: Breast cancer focus

Here we provide top-line summaries of results from three phase III breast cancer trials, evaluating nab-paclitaxel and a trastuzumab biosimilar in the nonmetastatic HER2-negative and -positive settings, respectively, and quality of life with the addition of palbociclib in the advanced or metastatic setting.

image credits